Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
5.20
+0.14 (2.77%)
At close: Feb 3, 2026, 4:00 PM EST
5.10
-0.10 (-1.90%)
After-hours: Feb 3, 2026, 8:00 PM EST
Perspective Therapeutics Employees
As of December 31, 2024, Perspective Therapeutics had 140 total employees, including 138 full-time and 2 part-time employees. The number of employees increased by 21 or 17.65% compared to the previous year.
Employees
140
Change (1Y)
21
Growth (1Y)
17.65%
Revenue / Employee
$7,679
Profits / Employee
-$755,714
Market Cap
386.56M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 140 | 21 | 17.65% | 138 | 2 |
| Dec 31, 2023 | 119 | 28 | 30.77% | 116 | 3 |
| Sep 30, 2023 | 91 | - | - | 91 | 0 |
| Jun 30, 2023 | 91 | - | - | 91 | 0 |
| Mar 31, 2023 | 91 | - | - | 91 | 0 |
| Jun 30, 2021 | 61 | 8 | 15.09% | 61 | 0 |
| Jun 30, 2020 | 53 | 10 | 23.26% | 53 | 0 |
| Jun 30, 2019 | 43 | 5 | 13.16% | 43 | 0 |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Viemed Healthcare | 1,380 |
| Cerus | 630 |
| OrthoPediatrics | 562 |
| RxSight | 498 |
| Quanterix | 471 |
| Sight Sciences | 216 |
| BrainsWay | 120 |
| Senseonics Holdings | 117 |
CATX News
- 1 day ago - Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 4 days ago - Perspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting Space - Seeking Alpha
- 19 days ago - Perspective Therapeutics, Inc. (CATX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 25 days ago - Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium - GlobeNewsWire
- 6 weeks ago - Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Perspective Therapeutics to Participate in Upcoming December Conferences - GlobeNewsWire
- 2 months ago - Perspective Therapeutics, Inc. (CATX) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 3 months ago - Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results - GlobeNewsWire